A citation-based method for searching scientific literature

Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J Carl Barrett, Ursula Matulonis. Lancet Oncol 2014
Times Cited: 841



Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin, Henri Roché, Young-Hyuck Im, Ruben G W Quek, Denka Markova, Iulia C Tudor, Alison L Hannah, Wolfgang Eiermann, Joanne L Blum. N Engl J Med 2018
Times Cited: 564




List of shared articles



Times cited

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Fengping Shao, Yaoyun Duan, Yunhe Zhao, Yinguang Li, Jun Liu, Cai Zhang, Shanyang He. Aging (Albany NY) 2021
1

PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.
Devashish Desai, Pushti Khandwala, Meghana Parsi, Rashmika Potdar. Med Oncol 2021
0

DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Ahrum Min, Kyung-Hun Lee, Seock-Ah Im. Adv Exp Med Biol 2021
0

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Zsofia K Stadler, Anna Maio, Debyani Chakravarty, Yelena Kemel, Margaret Sheehan, Erin Salo-Mullen, Kaitlyn Tkachuk, Christopher J Fong, Bastien Nguyen, Amanda Erakky,[...]. J Clin Oncol 2021
0

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021
0

Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021
0

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R Grimes, Robert L Hollis, C Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson,[...]. Clin Cancer Res 2021
0

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui, Liying Han. Curr Drug Targets 2020
5

Delving into PARP inhibition from bench to bedside and back.
Giovanni Grignani, Alessandra Merlini, Dario Sangiolo, Lorenzo D'Ambrosio, Ymera Pignochino. Pharmacol Ther 2020
3


[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
Meriem Koual, Géraldine Perkins, Nicolas Delanoy, Céline Crespel, Jacques Medioni, Huyên-Thu Nguyen-Xuan, Nathalie Douay-Hauser, Hélène Blons, Marie-Aude Le Frère-Belda, Diane Molière,[...]. Ann Pathol 2020
0

The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Madalena Tarsounas, Patrick Sung. Nat Rev Mol Cell Biol 2020
43

Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
Allen Li, Stephen M Schleicher, Fabrice Andre, Zahi I Mitri. Am Soc Clin Oncol Educ Book 2020
3

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis. Drugs R D 2020
30